A Prospective Clinical Study to Evaluate the Role of Centchroman in the Treatment of Mastalgia and ANDI (Aberrations of Normal Development and Involution) of the Breast Surgery
Abstract: Background: Benign breast disorders has been classified by the ANDI system (aberrations of normal development and involution of breast) and includes mastalgia, fibroadenoma among other disorders. Drugs used for these disorders are expensive with side effects and do not show any improvement. Ormeloxifene (Centchroman) is a selective estrogen modulator synthesized by the Central Drug Research Institute, Lucknow. It has been previously used in patients with mastalgia and fibroadenomaand has shown promising results. This study is being undertaken to understand the role of centchroman as an effective treatment for mastalgia and ANDI. Materials and Method: The present randomized control trial was conducted in the Department of Surgery, Rama Medical College Hospital & Research Centre, Mandhana, Kanpur, U. P which was conducted from January 2021 to September 2022. The study was conducted in two groupswith mastalgia and fibroadenoma. The trial was with 170 women of age 20 - 40 years with complaints of mastalgia (with or without nodularity) or with those with fibroadenoma
Keywords: ANDI, Centchroman, Mastalgia, Fibroadenoma, Benign, Breast
How to Cite?: Dr Ashita Kohli, Dr. Manisha Nigam, Dr. Brijendra Nigam, Dr. Surekha, "A Prospective Clinical Study to Evaluate the Role of Centchroman in the Treatment of Mastalgia and ANDI (Aberrations of Normal Development and Involution) of the Breast Surgery", Volume 12 Issue 3, March 2023, International Journal of Science and Research (IJSR), Pages: 1570-1575, https://www.ijsr.net/getabstract.php?paperid=SR23325084704, DOI: https://dx.doi.org/10.21275/SR23325084704